98%
921
2 minutes
20
Food effect summarization from New Drug Application (NDA) is an essential component of product-specific guidance (PSG) development and assessment, which provides the basis of recommendations for fasting and fed bioequivalence studies to guide the pharmaceutical industry for developing generic drug products. However, manual summarization of food effect from extensive drug application review documents is time-consuming. Therefore, there is a need to develop automated methods to generate food effect summary. Recent advances in natural language processing (NLP), particularly large language models (LLMs) such as ChatGPT and GPT-4, have demonstrated great potential in improving the effectiveness of automated text summarization, but its ability with regard to the accuracy in summarizing food effect for PSG assessment remains unclear. In this study, we introduce a simple yet effective approach,iterative prompting, which allows one to interact with ChatGPT or GPT-4 more effectively and efficiently through multi-turn interaction. Specifically, we propose a three-turn iterative prompting approach to food effect summarization in which the keyword-focused and length-controlled prompts are respectively provided in consecutive turns to refine the quality of the generated summary. We conduct a series of extensive evaluations, ranging from automated metrics to FDA professionals and even evaluation by GPT-4, on 100 NDA review documents selected over the past five years. We observe that the summary quality is progressively improved throughout the iterative prompting process. Moreover, we find that GPT-4 performs better than ChatGPT, as evaluated by FDA professionals (43% vs. 12%) and GPT-4 (64% vs. 35%). Importantly, all the FDA professionals unanimously rated that 85% of the summaries generated by GPT-4 are factually consistent with the golden reference summary, a finding further supported by GPT-4 rating of 72% consistency. Taken together, these results strongly suggest a great potential for GPT-4 to draft food effect summaries that could be reviewed by FDA professionals, thereby improving the efficiency of the PSG assessment cycle and promoting generic drug product development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jbi.2023.104533 | DOI Listing |
Curr Drug Deliv
September 2025
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
In recent years, tremendous progress in the field of novel drug delivery systems (NDDS), which has prompted the creation of new strategies to enhance treatment results and patient compliance. The goal of this comprehensive review is to provide a summary of the NDDS that the US Food and Drug Administration (USFDA) has approved from 2019 to 2023. Various databases, including PubMed, Scopus, USFDA, and patent websites were utilized to gather relevant information.
View Article and Find Full Text PDFToxicon
September 2025
Research and Innovation Hub, Innovation Aesthetics, London UK.
Botulinum Neurotoxin Type A (BoNT-A) remains the cornerstone of glabellar frown line treatment, yet conventional low-dose, high-volume protocols often result in limited durability and imprecise diffusion. This study presents multiscale, in silico framework specifically designed to evaluate high-dose (60-80 Units), low-volume (≤0.045 mL/site) BoNT-A glabellar injection strategies across anatomically realistic conditions.
View Article and Find Full Text PDFWorld J Methodol
December 2025
Department of Cardiology, University of Miami-Miller School of Medicine, Miami, FL 33136, United States.
Background: The Food and Drug Administration has approved percutaneous atrial septal defect (ASD) and patent foramen ovale (PFO) closure devices for hemodynamically significant interatrial shunts, paradoxical emboli including stroke, and decompression sickness. We aimed to study the trends in utilization and reimbursements of transcatheter ASD/PFO closure devices.
Aim: To analyze trends in utilization and Medicare reimbursements for transcatheter ASD/PFO closure procedures from 2013 to 2022.
Front Psychiatry
August 2025
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Objective: Zuranolone, the latest oral medication for postpartum depression, was approved in the United States in August 2023. Due to its pharmacokinetic characteristics and rapid onset of action, it is hailed as a breakthrough and enhanced version of the drug. However, there is limited information on adverse drug reactions associated with its use.
View Article and Find Full Text PDFActa Biomater
August 2025
Department of Chemistry, Binghamton University, State University of New York, Binghamton, NY, USA. Electronic address:
Guidance recently released by the Food and Drug Administration (FDA) regarding tattoo inks describes tattooing as an injection process, but is injection the correct terminology to use when describing tattooing? This perspective aims to provide a brief overview of the core mechanics and science behind injection and tattoo processes, as well as emphasize the importance of using the correct terminology when referencing tattoos and the act of tattooing moving forward. STATEMENT OF SIGNIFICANCE: Due to a change in the FDA regulatory framework around cosmetics in December 2022, for the first time the FDA is in the process of actively regulating tattoo inks. Central to how tattoos will be regulated is whether tattoos and tattooing should be considered an injectable process.
View Article and Find Full Text PDF